Kelun Pharmaceutical Receives USD 35 Million from Merck Sharp & Dohme Corp.
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that it has received a USD...
Merck Sharp & Dohme
Walvax Biotech Enrolls First Subject in Phase III HPV Vaccine Study
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced the first subject enrollment for a Phase...
Merck’s Gardasil 9-Valent HPV Vaccine Approved for Expanded Age Range in China
US-based Merck Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...
Merck Launches Prevymis, a Non-Nucleoside CMV Inhibitor, in China
US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of...
Merck’s Q2 Sales Surge 31% to USD 14.6B, Led by Keytruda and China Growth
US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) reported Q2 2022 global sales of USD...
Sichuan Kelun Pharmaceutical and Merck Sharp & Dohme Corp. Ink Second ADC Licensing Deal
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme...
Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC
The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...
Kelun Pharmaceutical Receives USD 30 Million from MSD for Licensing Deal
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced receiving USD 30 million from...